<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02229422</url>
  </required_header>
  <id_info>
    <org_study_id>140396</org_study_id>
    <nct_id>NCT02229422</nct_id>
  </id_info>
  <brief_title>A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 &amp; HDMP)</brief_title>
  <acronym>GA101 &amp; HDMP</acronym>
  <official_title>A Study of Obinutuzumab in Combination With High-Dose Methylprednisolone in Chronic Lymphocytic Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that GA101 - Obinutuzumab in combination with HDMP is well tolerated and will&#xD;
      induce similar if not higher response rates than the ones observed in Rituximab plus HDMP&#xD;
      studies (Castro et al., 2009, Castro et al., 2008).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label phase Ib/II clinical trial to determine the safety and clinical&#xD;
      activity of the GA101 - Obinutuzumab in combination with high-dose methylprednisone (HDMP).&#xD;
      We will evaluate dose-limiting toxicities (DLTs) during the first month of therapy as part of&#xD;
      the phase Ib of this study. In the phase II we will determine response rate in an intention&#xD;
      to treat analysis. In this study we will include CLL patients that have never received&#xD;
      treatment as well as patients that have failed previous treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events that constitute the Dose Limiting Toxicity</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response assessment based on IWCLL</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival and Minimal residual disease (MRD)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>CLL</condition>
  <arm_group>
    <arm_group_label>GA101/HDMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:&#xD;
On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.&#xD;
On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.&#xD;
On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.&#xD;
On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.&#xD;
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:&#xD;
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GA101/HDMP</intervention_name>
    <description>All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:&#xD;
On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.&#xD;
On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.&#xD;
On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.&#xD;
On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.&#xD;
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:&#xD;
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.</description>
    <arm_group_label>GA101/HDMP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of CLL&#xD;
&#xD;
          2. Indication for treatment as defined by the IWCLL Guidelines (Hallek et al., 2008b).&#xD;
&#xD;
          3. Males and females 18 years of age and older.&#xD;
&#xD;
          4. Laboratory parameters as specified below:&#xD;
&#xD;
               -  Hematologic: Hemoglobin &gt; 8 g/dL (may be post-transfusion); platelet count &gt; 40&#xD;
                  x103/mm3 (may be post-transfusion). Absolute neutrophil count &gt; 1.0 109 cells/mm3&#xD;
                  (Growth factor use is allowed).&#xD;
&#xD;
               -  Hepatic: Total Bilirubin &lt; 3 x ULN, and ALT and AST &lt; 3 x ULN&#xD;
&#xD;
               -  Renal: Creatinine clearance &gt; 30 mL/min (Calculated according to institutional&#xD;
                  standards or using Cockcroft-Gault formula. Subjects with requirement of&#xD;
                  hemodialysis will be excluded).&#xD;
&#xD;
          5. ECOG Performance Status &lt; 2, unless the decline of the performance status is&#xD;
             considered to be related to CLL symptoms.&#xD;
&#xD;
          6. Anticipated survival of at least 6 months.&#xD;
&#xD;
          7. Subjects can be enrolled and treated under this protocol regardless of their CLL&#xD;
             treatment history or number of previous treatments. In addition, subjects with history&#xD;
             of allogeneic stem cell transplant can be enrolled and treated unless they have active&#xD;
             manifestations of graft vs. host disease (GVHD) or chronic illness or infections that&#xD;
             will prevent them from completing the study.&#xD;
&#xD;
          8. Previously untreated subjects that meet ANY of the following criteria: A. Documented&#xD;
             refusal to be treated with chemotherapy agents. B. Subjects that are not candidates&#xD;
             for treatment with chemotherapy based on poor performance status (ECOG ≥ 2), advance&#xD;
             age (&gt; 65 years), Cumulative Illness Rating Scale (CIRS score) ≥ 6 or cytopenias.&#xD;
&#xD;
          9. Effective contraception is required while receiving GA101 - Obinutuzumab. For women of&#xD;
             childbearing potential and men, effective contraception is required while receiving&#xD;
             GA101 - Obinutuzumab and for 365 days (12 months) after the last dose of the study&#xD;
             drug.&#xD;
&#xD;
         10. Ability to understand the requirements of the study, provide written informed consent&#xD;
             and authorization of use and disclosure of protected health information, and agree to&#xD;
             abide by the study restrictions and return for the required assessments.&#xD;
&#xD;
         11. Subjects must give written informed consent to participate in this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing women.&#xD;
&#xD;
          2. Treatment with chemotherapy, monoclonal antibodies or biological agents (e.g.&#xD;
             Ibrutinib, lenalidomide) within 28 days prior to entering the study.&#xD;
&#xD;
          3. Treatment with chemotherapy, monoclonal antibodies, biological agents (e.g. Ibrutinib)&#xD;
             or other than the investigational agents during the time of participation in this&#xD;
             trial.&#xD;
&#xD;
          4. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional&#xD;
             Classification.&#xD;
&#xD;
          5. Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of&#xD;
             breath, COPD)&#xD;
&#xD;
          6. Participation in any investigational drug study within 28 days prior to initiation of&#xD;
             treatment within this protocol.&#xD;
&#xD;
          7. History of second malignancy, other than non-melanoma skin cancer or in situ carcinoma&#xD;
             of the cervix or the breast, unless the tumor was successfully treated at least 2&#xD;
             years before trial entry and with no evidence of relapse or active cancer.&#xD;
&#xD;
          8. Active symptomatic fungal, bacterial and/or viral infection including evidence of&#xD;
             infection with HIV, human T-cell leukemia virus 1 (HTLV-1) seropositive status.&#xD;
&#xD;
          9. Evidence of active acute or chronic Hepatitis B (HBV).&#xD;
&#xD;
         10. Evidence of active Hepatitis C (HCV): subjects with positive hepatitis C serology AND&#xD;
             positive HCV RNA test.&#xD;
&#xD;
         11. Any illness or condition that in the opinion of the Investigator may affect safety of&#xD;
             treatment or evaluation of any the study's endpoints.&#xD;
&#xD;
         12. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy&#xD;
&#xD;
         13. Known hypersensitivity to any of the study drugs.&#xD;
&#xD;
         14. Major surgery (within 4 weeks prior to the start of Cycle 1), except for procedures&#xD;
             that are performed for diagnostic purposes.&#xD;
&#xD;
         15. Men or women of childbearing potential who refuse to use an adequate measure of&#xD;
             contraception (oral contraceptives, intrauterine device, or barrier method of&#xD;
             contraception in conjunction with spermicidal jelly) unless they have past medical&#xD;
             history of surgical sterilization.&#xD;
&#xD;
         16. Vaccination with a live vaccine within 28 days of the initiation of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kipps Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <last_update_submitted>August 29, 2023</last_update_submitted>
  <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Thomas Kipps</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02229422
org study id: 140396
nct id: NCT02229422
lead sponsor: 
collaborator: 
has dmc: Yes
We hypothesize that GA101 - Obinutuzumab in combination with HDMP is well tolerated and will
      induce similar if not higher response rates than the ones observed in Rituximab plus HDMP
      studies (Castro et al., 2009, Castro et al., 2008).
This is an open label phase Ib/II clinical trial to determine the safety and clinical
      activity of the GA101 - Obinutuzumab in combination with high-dose methylprednisone (HDMP).
      We will evaluate dose-limiting toxicities (DLTs) during the first month of therapy as part of
      the phase Ib of this study. In the phase II we will determine response rate in an intention
      to treat analysis. In this study we will include CLL patients that have never received
      treatment as well as patients that have failed previous treatments.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Adverse events that constitute the Dose Limiting Toxicity
time frame: 2 months
measure: Response assessment based on IWCLL
time frame: 2 months
measure: Progression Free Survival
time frame: 2 years
measure: Overall Survival and Minimal residual disease (MRD)
time frame: 2 years
arm group label: GA101/HDMP
arm group type: Experimental
description: All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.
On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.
On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.
On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.
intervention type: Drug
intervention name: GA101/HDMP
description: All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.
On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.
On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.
On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.
arm group label: GA101/HDMP
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Kipps Thomas, MD
role: Principal Investigator
affiliation: University of California, San Diego
facility: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: University of California, San Diego
investigator full name: Thomas Kipps
investigator title: Associate Clinical Professor
mesh term: Leukemia, Lymphoid
mesh term: Leukemia, Lymphocytic, Chronic, B-Cell
mesh term: Obinutuzumab